LYNCH Biologics

Lynch Biologics ("LBIO" or "the company") is a biotechnology company focused on regenerative medicine, using specialized bioactive proteins to help healthcare service providers offer treatment solutions to patients experiencing a range of difficult conditions from diabetic foot ulcers to major dental surgeries and various issues from head to toe. This mission is achieved through the commercialization of innovative biologics, biomaterials, and cell therapies obtained via mergers and acquisitions, licensing, and internal research and development. Commercial promotion is carried out through a direct sales force in the United States and licensed partners around the world. The company currently has four key business areas: improving wound healing such as diabetic foot ulcers and post-surgical wound complications, dental/craniofacial bone and soft tissue regeneration, supplying protein growth factors for the manufacture of mesenchymal stem cell therapies, and business globalization. Dr. Sam Lynch, founder and CEO of LBIO, is the original founder and former CEO of BioMimetic Therapeutics, Inc. He is the inventor of this technology and led the team to successfully obtain market approval in the U.S. and international markets for GEM 21S and Augment Bone Graft.